Barclays Maintains Overweight on Xylem, Lowers Price Target to $154

Benzinga Newsdesk www.benzinga.com Negative 82.6%

Neg 82.6% Neu 0% Pos 0%

Barclays analyst William Grippin maintains Xylem (NYSE:XYL) with a Overweight and lowers the price target from $156 to $154.